CUMYL-THPINACA
Synthetic cannabinoid of the indazole-3-carboxamide family, scheduled as a narcotic in France.
C₂₃H₂₇N₃O₂
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- 1-(oxan-4-ylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide
- Other names
- SGT-42
Identifiers
- Formula
- C₂₃H₂₇N₃O₂
- Molar mass
- 377.50 g/mol
- CAS
- 1400742-50-8
- PubChem CID
- 86273679(new tab)
- InChIKey
- HINCNLQQLQFMRD-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
Updated on
Receptors and activity
- CB1Agonist88 out of 100
Affinité nanomolaire faible, sans Ki chiffré dans le texte consulté ; présentée comme du même ordre que le Ki CB2 de 1,38 nM (Schoeder et coll., 2018)
- CB2Agonist90 out of 100
Ki = 1,38 nM (récepteur humain, cellules CHO ; Schoeder et coll., 2018)
Subjective signature
- Calm
- 12 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 5 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 15 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 15 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 10 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
CUMYL-THPINACA is a synthetic cannabinoid of the indazole-3-carboxamide family, which binds the CB1 and CB2 receptors with nanomolar affinity: a Ki of 1.38 nM was measured at CB2. Its N1 chain is a tetrahydropyranylmethyl group, and its amide head carries a cumyl group. Published data remain limited to in vitro pharmacology and metabolism: they describe rapid transformation, with 28 metabolites detected in pooled human liver microsomes (Monti et al., 2021), and an in vitro half-life of 4.9 min (Azuma et al., 2024). No clinical study, no animal data and no documented case appear in the sources consulted. The molecule is scheduled by name as a narcotic in France.
Key sources.
- Schoeder et coll., évaluation pharmacologique de nouveaux constituants du « Spice », Forensic Toxicology, 2018 (new tab)PMID 29963207
- Azuma et coll., structure d'un métabolite de CUMYL-THPINACA hydroxylé sur le groupe cumyle, Drug Testing and Analysis, 2024 (new tab)PMID 37485784
- Monti et coll., profil métabolique de phase I de CUMYL-THPINACA et ADAMANTYL-THPINACA, Metabolites, 2021 (new tab)PMID 34436411
- ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, dérivés du 3-carboxamide indazole) (new tab)
- OICS, Liste verte 2026 (substances des conventions internationales), molécule non inscrite (new tab)
- PubChem, CUMYL-THPINACA, CID 86273679 (new tab)
History
- Source
- Entirely synthetic molecule, described as such in the sources consulted. It belongs to the family of cumyl-headed indazole-3-carboxamides, and the French list also designates it by the code SGT-42. Its systematic name is 1-(oxan-4-ylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide. Cumyl derivatives have recently been found in materials seized from the illicit market (Schoeder et al., 2018).
Origin (pharmaceutical research → illicit market)
No biosynthetic pathway: entirely synthetic molecule, obtained by clandestine chemical synthesis according to the indazole-3-carboxamide class.
Legal framework
- European Union
No harmonised European Union control measure for this molecule was found in the sources consulted: its control rests on national legislation.
- France
In France, CUMYL-THPINACA is scheduled by name as a narcotic. The ANSM consolidated list of 16 February 2026 mentions it in annex IV, within the generic definition of 3-carboxamide indazole derivatives, where it is cited in the « Notamment » list under the name « CUMYL-THPINACA ou SGT-42 ». Its structure also meets the conditions of that definition: a methyl-oxane substituent on the N1 position of the indazole ring, and a cumyl group on the carboxamide bridge nitrogen. Possession, transfer and use fall under the criminal regime for narcotics.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Schoeder et coll., évaluation pharmacologique de nouveaux constituants du « Spice », Forensic Toxicology, 2018 (new tab)PMID 29963207
- Azuma et coll., structure d'un métabolite de CUMYL-THPINACA hydroxylé sur le groupe cumyle, Drug Testing and Analysis, 2024 (new tab)PMID 37485784
- Monti et coll., profil métabolique de phase I de CUMYL-THPINACA et ADAMANTYL-THPINACA, Metabolites, 2021 (new tab)PMID 34436411
- ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, dérivés du 3-carboxamide indazole) (new tab)
- OICS, Liste verte 2026 (substances des conventions internationales), molécule non inscrite (new tab)
- PubChem, CUMYL-THPINACA, CID 86273679 (new tab)
Structured data
- SMILES
- CC(C)(NC(=O)c1nn(CC2CCOCC2)c2ccccc12)c1ccccc1
- InChIKey
- HINCNLQQLQFMRD-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.